Matches in SemOpenAlex for { <https://semopenalex.org/work/W2337280511> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2337280511 endingPage "20526" @default.
- W2337280511 startingPage "20526" @default.
- W2337280511 abstract "20526 Background: Bisphosphonate (BP) therapy is indicated in the treatment of pts. with symptomatic bony disease secondary to myeloma, solid tumors and in the treatment of osteoporosis. We have previously reported our experience with BP related osteonecrosis of the jaw (ONJ) (J Oral Maxillofac Surg 2004;62:527–34). The reported incidence of this entity in patients receiving IV BP’s is approx. 1–10%. The purpose of our current report is to update our experience and report the clinical outcome of the osteonecrotic lesion, with particular emphasis to clinical stage and after following stage specific management guidelines that we have previously published (Hematology 2006; 356–360). Methods: We performed a retrospective analysis of pts. records that were diagnosed with ONJ at our institution. IRB approval was obtained for this study. Information regarding age, gender, indication for BP treatment, type of BP used, stage of ONJ at time of presentation, outcome of ONJ with appropriate therapy were recorded. Results: Two hundred and seven pts. with ONJ were identified at our institution. Males: n=52; Females: n=155. Underlying frequent diagnoses: Myeloma: n=71; breast ca: n=68; osteoporosis: n=42; prostate ca: n=11; others: n=13. Prior BP therapy included exposure to pamidronate: n=87; zoledronic acid: n=123; oral BP: n=41. Ninety four patients were serially followed for outcome data regarding clinical course of ONJ after cessation of BP therapy. Improvement in ONJ was noted: n=24 (26%), stable disease: n=52 (55%), worsening of ONJ: n=18 (19%). Their initial stage of ONJ was recorded as Stage 1: n=26 (28%), Stage 2: n=45 (48%), Stage 3: n=23 (24%). Outcome by stage: stage 1 pts: improvement 19%; stable disease 73%, worsening 8%; Stage 2 pts: improvement noted in 31%, stable disease 47%, worsening 22%; Stage 3 pts: improvement in 22%, stable disease 52%, worsening 26%. Conclusions: With early detection at a lower stage, and careful conservative management, the large majority (74–92%) of pts. presenting with ONJ will have stabilization or improvement in their clinical presentation after discontinuation of BP therapy. Close coordination of care between oncologists and dental colleagues may optimize treatment outcomes with this entity. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen, Novartis Novartis" @default.
- W2337280511 created "2016-06-24" @default.
- W2337280511 creator A5033886763 @default.
- W2337280511 creator A5057647897 @default.
- W2337280511 creator A5062043313 @default.
- W2337280511 date "2008-05-20" @default.
- W2337280511 modified "2023-10-18" @default.
- W2337280511 title "Outcomes of bisphosphonate-related osteonecrosis of the jaw—Importance of staging and management guidelines: A large single institutional update" @default.
- W2337280511 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.20526" @default.
- W2337280511 hasPublicationYear "2008" @default.
- W2337280511 type Work @default.
- W2337280511 sameAs 2337280511 @default.
- W2337280511 citedByCount "23" @default.
- W2337280511 countsByYear W23372805112012 @default.
- W2337280511 countsByYear W23372805112013 @default.
- W2337280511 countsByYear W23372805112014 @default.
- W2337280511 countsByYear W23372805112015 @default.
- W2337280511 countsByYear W23372805112017 @default.
- W2337280511 countsByYear W23372805112019 @default.
- W2337280511 countsByYear W23372805112021 @default.
- W2337280511 crossrefType "journal-article" @default.
- W2337280511 hasAuthorship W2337280511A5033886763 @default.
- W2337280511 hasAuthorship W2337280511A5057647897 @default.
- W2337280511 hasAuthorship W2337280511A5062043313 @default.
- W2337280511 hasConcept C120665830 @default.
- W2337280511 hasConcept C121332964 @default.
- W2337280511 hasConcept C126322002 @default.
- W2337280511 hasConcept C141071460 @default.
- W2337280511 hasConcept C146357865 @default.
- W2337280511 hasConcept C151730666 @default.
- W2337280511 hasConcept C167135981 @default.
- W2337280511 hasConcept C195910791 @default.
- W2337280511 hasConcept C2776326535 @default.
- W2337280511 hasConcept C2776364478 @default.
- W2337280511 hasConcept C2776541429 @default.
- W2337280511 hasConcept C2777251235 @default.
- W2337280511 hasConcept C2777556957 @default.
- W2337280511 hasConcept C61511704 @default.
- W2337280511 hasConcept C71924100 @default.
- W2337280511 hasConcept C86803240 @default.
- W2337280511 hasConceptScore W2337280511C120665830 @default.
- W2337280511 hasConceptScore W2337280511C121332964 @default.
- W2337280511 hasConceptScore W2337280511C126322002 @default.
- W2337280511 hasConceptScore W2337280511C141071460 @default.
- W2337280511 hasConceptScore W2337280511C146357865 @default.
- W2337280511 hasConceptScore W2337280511C151730666 @default.
- W2337280511 hasConceptScore W2337280511C167135981 @default.
- W2337280511 hasConceptScore W2337280511C195910791 @default.
- W2337280511 hasConceptScore W2337280511C2776326535 @default.
- W2337280511 hasConceptScore W2337280511C2776364478 @default.
- W2337280511 hasConceptScore W2337280511C2776541429 @default.
- W2337280511 hasConceptScore W2337280511C2777251235 @default.
- W2337280511 hasConceptScore W2337280511C2777556957 @default.
- W2337280511 hasConceptScore W2337280511C61511704 @default.
- W2337280511 hasConceptScore W2337280511C71924100 @default.
- W2337280511 hasConceptScore W2337280511C86803240 @default.
- W2337280511 hasIssue "15_suppl" @default.
- W2337280511 hasLocation W23372805111 @default.
- W2337280511 hasOpenAccess W2337280511 @default.
- W2337280511 hasPrimaryLocation W23372805111 @default.
- W2337280511 hasRelatedWork W1769645042 @default.
- W2337280511 hasRelatedWork W2016541062 @default.
- W2337280511 hasRelatedWork W2049848179 @default.
- W2337280511 hasRelatedWork W2062144032 @default.
- W2337280511 hasRelatedWork W2129227047 @default.
- W2337280511 hasRelatedWork W2189375897 @default.
- W2337280511 hasRelatedWork W2297653040 @default.
- W2337280511 hasRelatedWork W2333447821 @default.
- W2337280511 hasRelatedWork W2405383550 @default.
- W2337280511 hasRelatedWork W4226070154 @default.
- W2337280511 hasVolume "26" @default.
- W2337280511 isParatext "false" @default.
- W2337280511 isRetracted "false" @default.
- W2337280511 magId "2337280511" @default.
- W2337280511 workType "article" @default.